Literature DB >> 29775806

CD103+CD8+ Lymphocytes Characterize the Immune Infiltration in a Case With Pseudoprogression in Squamous NSCLC.

Pedro Rocha1, Max Hardy-Werbin2, Dolores Naranjo3, Álvaro Taus1, Maite Rodrigo3, Flavio Zuccarino4, René Roth5, Oliver Wood6, Christian H Ottensmeier6, Edurne Arriola7.   

Abstract

Entities:  

Keywords:  CD103; Immunotherapy; Lung neoplasm; PD-1 inhibitor; Pseudoprogression

Mesh：

Substances：

Year:  2018        PMID： 29775806     DOI： 10.1016/j.jtho.2018.05.008

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  10 in total

1.  [A Case of Pseudoprogression During Atezolizumab Therapy 
in Lung Adenocarcinoma].

Authors:  Xue Wang; Yi Zhao; Zhiwei Chen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2019-06-20

2.  Case Report: Transformation From Cold to Hot Tumor in a Case of NSCLC Neoadjuvant Immunochemotherapy Pseudoprogression.

Authors:  Wenxiao Jia; Hui Zhu; Qianqian Gao; Jian Sun; Fujian Tan; Qun Liu; Hongbo Guo; Jinming Yu
Journal:  Front Immunol       Date:  2021-02-17       Impact factor: 7.561

3.  Clinical outcomes of hyperprogression based on volumetry in non-small cell lung cancer after immune checkpoint inhibitor treatment.

Authors:  Jehun Kim; Taeyun Kim; Tae Won Jang; Hee Kang; Mi Hyun Kim; Seong Hoon Yoon; Choon-Hee Son; Hyun-Kyung Lee; Hyun-Kuk Kim; Shin Yup Lee; Kyeong Choel Shin; Ji-Yeon Han; Eun-Ju Kang
Journal:  Thorac Cancer       Date:  2022-07-03       Impact factor: 3.223

4.  Pseudoprogression in lung cancer: a case report.

Authors:  Giulia Meoni; Nicola Libertà Decarli; Maurizio Benucci; Claudio Raspanti; Angela Stefania Ribecco
Journal:  Explor Target Antitumor Ther       Date:  2020-10-30

Review 5.  Immune response evaluation criteria in solid tumors for assessment of atypical responses after immunotherapy.

Authors:  Davide Ippolito; Cesare Maino; Maria Ragusi; Marco Porta; Davide Gandola; Cammillo Talei Franzesi; Teresa Paola Giandola; Sandro Sironi
Journal:  World J Clin Oncol       Date:  2021-05-24

6.  A Novel Immune-Related Seventeen-Gene Signature for Predicting Early Stage Lung Squamous Cell Carcinoma Prognosis.

Authors:  Tao Fan; Zhiliang Lu; Yu Liu; Liyu Wang; He Tian; Yujia Zheng; Bo Zheng; Liyan Xue; Fengwei Tan; Qi Xue; Shugeng Gao; Chunxiang Li; Jie He
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 7.561

Review 7.  How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?

Authors:  Morgane Denis; Michael Duruisseaux; Marie Brevet; Charles Dumontet
Journal:  Front Immunol       Date:  2020-03-20       Impact factor: 7.561

8.  The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy.

Authors:  Wenxiao Jia; Qianqian Gao; Anqin Han; Hui Zhu; Jinming Yu
Journal:  Cancer Biol Med       Date:  2019-11       Impact factor: 4.248

9.  Disease progression and pseudoprogression following partial response with rare gingiva metastasis upon IBI308 (sintilimab) immunotherapy reflects the complexity of metastatic lung cancer: a case report.

Authors:  Haiping Jiang; Lele Song; Zhenguang Chen; Yuan Gao; Yongfeng Ding; Qihan You; Lei Ye; Lifeng Li; Guifeng Liu; Nong Xu
Journal:  Transl Cancer Res       Date:  2021-01       Impact factor: 1.241

Review 10.  Clinicopathological implications of lncRNAs, immunotherapy and DNA methylation in lung squamous cell carcinoma: a narrative review.

Authors:  Gabriel B K Sasa; Cheng Xuan; Meiyue Chen; Zhenggang Jiang; Xianfeng Ding
Journal:  Transl Cancer Res       Date:  2021-12       Impact factor: 1.241
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.